Identification of approved drugs that inhibit the binding of amyloid β oligomers to ephrin type-B receptor 2

Koichiro Suzuki, Takahiro Aimi, Tomoaki Ishihara, Tohru Mizushima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ephrin type-B receptor 2 (EphB2) is a member of the receptor tyrosine kinase family and plays an important role in learning and memory functions. In patients with Alzheimer's disease (AD) and in mouse models of AD, a reduction in the hippocampal EphB2 level is observed. It was recently reported that normalization of the EphB2 level in the dentate gyrus rescues memory function in a mouse model of AD, suggesting that drugs that restore EphB2 levels may be beneficial in the treatment of AD. Amyloid β (Aβ) oligomers, which are believed to be key molecules involved in the pathogenesis of AD, induce EphB2 degradation through their direct binding to EphB2. Thus, compounds that inhibit the binding of Aβ oligomers to EphB2 may be beneficial. Here, we screened for such compounds from drugs already approved for clinical use in humans. Utilizing a cell-free screening assay, we determined that dihydroergotamine mesilate, bromocriptine mesilate, cepharanthine, and levonorgestrel inhibited the binding of Aβ oligomers to EphB2 but not to cellular prion protein, another endogenous receptor for Aβ oligomers. Additionally, these four compounds did not affect the binding between EphB2 and ephrinB2, an endogenous ligand for EphB2, suggesting that the compounds selectively inhibited the binding of Aβ oligomers to EphB2. This is the first identification of compounds that selectively inhibit the binding of Aβ oligomers to EphB2. These results suggest that these four compounds may be safe and effective drugs for treatment of AD.

Original languageEnglish
JournalFEBS Open Bio
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Eph Family Receptors
Oligomers
Amyloid
Alzheimer Disease
Pharmaceutical Preparations
Mesylates
Dihydroergotamine
Data storage equipment
Levonorgestrel
Bromocriptine
Dentate Gyrus
Receptor Protein-Tyrosine Kinases
Assays
Screening
Learning
Ligands
Degradation
Molecules
Therapeutics

Keywords

  • Alzheimer's disease
  • Amyloid β oligomer
  • Ephrin type-B receptor 2

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Identification of approved drugs that inhibit the binding of amyloid β oligomers to ephrin type-B receptor 2. / Suzuki, Koichiro; Aimi, Takahiro; Ishihara, Tomoaki; Mizushima, Tohru.

In: FEBS Open Bio, 2016.

Research output: Contribution to journalArticle

Suzuki, Koichiro ; Aimi, Takahiro ; Ishihara, Tomoaki ; Mizushima, Tohru. / Identification of approved drugs that inhibit the binding of amyloid β oligomers to ephrin type-B receptor 2. In: FEBS Open Bio. 2016.
@article{d254716b0d2d4ad3afd50289c845fc49,
title = "Identification of approved drugs that inhibit the binding of amyloid β oligomers to ephrin type-B receptor 2",
abstract = "Ephrin type-B receptor 2 (EphB2) is a member of the receptor tyrosine kinase family and plays an important role in learning and memory functions. In patients with Alzheimer's disease (AD) and in mouse models of AD, a reduction in the hippocampal EphB2 level is observed. It was recently reported that normalization of the EphB2 level in the dentate gyrus rescues memory function in a mouse model of AD, suggesting that drugs that restore EphB2 levels may be beneficial in the treatment of AD. Amyloid β (Aβ) oligomers, which are believed to be key molecules involved in the pathogenesis of AD, induce EphB2 degradation through their direct binding to EphB2. Thus, compounds that inhibit the binding of Aβ oligomers to EphB2 may be beneficial. Here, we screened for such compounds from drugs already approved for clinical use in humans. Utilizing a cell-free screening assay, we determined that dihydroergotamine mesilate, bromocriptine mesilate, cepharanthine, and levonorgestrel inhibited the binding of Aβ oligomers to EphB2 but not to cellular prion protein, another endogenous receptor for Aβ oligomers. Additionally, these four compounds did not affect the binding between EphB2 and ephrinB2, an endogenous ligand for EphB2, suggesting that the compounds selectively inhibited the binding of Aβ oligomers to EphB2. This is the first identification of compounds that selectively inhibit the binding of Aβ oligomers to EphB2. These results suggest that these four compounds may be safe and effective drugs for treatment of AD.",
keywords = "Alzheimer's disease, Amyloid β oligomer, Ephrin type-B receptor 2",
author = "Koichiro Suzuki and Takahiro Aimi and Tomoaki Ishihara and Tohru Mizushima",
year = "2016",
doi = "10.1002/2211-5463.12056",
language = "English",
journal = "FEBS Open Bio",
issn = "2211-5463",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Identification of approved drugs that inhibit the binding of amyloid β oligomers to ephrin type-B receptor 2

AU - Suzuki, Koichiro

AU - Aimi, Takahiro

AU - Ishihara, Tomoaki

AU - Mizushima, Tohru

PY - 2016

Y1 - 2016

N2 - Ephrin type-B receptor 2 (EphB2) is a member of the receptor tyrosine kinase family and plays an important role in learning and memory functions. In patients with Alzheimer's disease (AD) and in mouse models of AD, a reduction in the hippocampal EphB2 level is observed. It was recently reported that normalization of the EphB2 level in the dentate gyrus rescues memory function in a mouse model of AD, suggesting that drugs that restore EphB2 levels may be beneficial in the treatment of AD. Amyloid β (Aβ) oligomers, which are believed to be key molecules involved in the pathogenesis of AD, induce EphB2 degradation through their direct binding to EphB2. Thus, compounds that inhibit the binding of Aβ oligomers to EphB2 may be beneficial. Here, we screened for such compounds from drugs already approved for clinical use in humans. Utilizing a cell-free screening assay, we determined that dihydroergotamine mesilate, bromocriptine mesilate, cepharanthine, and levonorgestrel inhibited the binding of Aβ oligomers to EphB2 but not to cellular prion protein, another endogenous receptor for Aβ oligomers. Additionally, these four compounds did not affect the binding between EphB2 and ephrinB2, an endogenous ligand for EphB2, suggesting that the compounds selectively inhibited the binding of Aβ oligomers to EphB2. This is the first identification of compounds that selectively inhibit the binding of Aβ oligomers to EphB2. These results suggest that these four compounds may be safe and effective drugs for treatment of AD.

AB - Ephrin type-B receptor 2 (EphB2) is a member of the receptor tyrosine kinase family and plays an important role in learning and memory functions. In patients with Alzheimer's disease (AD) and in mouse models of AD, a reduction in the hippocampal EphB2 level is observed. It was recently reported that normalization of the EphB2 level in the dentate gyrus rescues memory function in a mouse model of AD, suggesting that drugs that restore EphB2 levels may be beneficial in the treatment of AD. Amyloid β (Aβ) oligomers, which are believed to be key molecules involved in the pathogenesis of AD, induce EphB2 degradation through their direct binding to EphB2. Thus, compounds that inhibit the binding of Aβ oligomers to EphB2 may be beneficial. Here, we screened for such compounds from drugs already approved for clinical use in humans. Utilizing a cell-free screening assay, we determined that dihydroergotamine mesilate, bromocriptine mesilate, cepharanthine, and levonorgestrel inhibited the binding of Aβ oligomers to EphB2 but not to cellular prion protein, another endogenous receptor for Aβ oligomers. Additionally, these four compounds did not affect the binding between EphB2 and ephrinB2, an endogenous ligand for EphB2, suggesting that the compounds selectively inhibited the binding of Aβ oligomers to EphB2. This is the first identification of compounds that selectively inhibit the binding of Aβ oligomers to EphB2. These results suggest that these four compounds may be safe and effective drugs for treatment of AD.

KW - Alzheimer's disease

KW - Amyloid β oligomer

KW - Ephrin type-B receptor 2

UR - http://www.scopus.com/inward/record.url?scp=84962786656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962786656&partnerID=8YFLogxK

U2 - 10.1002/2211-5463.12056

DO - 10.1002/2211-5463.12056

M3 - Article

AN - SCOPUS:84962786656

JO - FEBS Open Bio

JF - FEBS Open Bio

SN - 2211-5463

ER -